@article{4210c3503e20446587dd14619d4b5e3d,
title = "Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial",
abstract = "This phase I study in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of s.c. treatment of human recombinant interleukin 21 (IL-21).",
author = "Henrik Schmidt and Janet Brown and Ulrik Mouritzen and Peter Selby and Kirsten Fode and Svane, {Inge Marie} and Cook, {Graham P} and Mollerup, {David Hal} and Geertsen, {Poul F}",
note = "{\textcopyright}2010 AACR.",
year = "2010",
month = nov,
day = "1",
doi = "http://dx.doi.org/10.1158/1078-0432.CCR-10-1809",
language = "English",
volume = "16",
pages = "5312--9",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research (A A C R)",
number = "21",
}